ClinicalTrials.gg
RecruitingNCT07188220Updated Sep 23, 2025

Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study

An observational study in Metabolic Dysfunction Associated Steatohepatitis (MASH), sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.

Started
2025
with 2 others
Observational
5 of 28
4 open now
Primary completion
2027-12
later than 4 of 11 live
Registered
24th of 28
by date
Lead sponsor
3 of 28
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Among the 28 studies in Fatty Liver with a site in Spain, this one is one of 3 that started in 2025, is one of 5 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 24th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Fatty Liver with a site in Spain, or all of them as a file.
02

Study summary

The aim of this qualitative study is to explore and identify the expectations, perceptions, attitudes, needs, and knowledge related to the management of metabolic dysfunction-associated steatohepatitis (MASH) in patients diagnosed with this condition, before and after their participation in the MASH-Cardiovascular Programme at Hospital de la Santa Creu i Sant Pau, Barcelona.

The main research question is:

What expectations, attitudes, needs, and perceptions do patients with MASH participating in the MASH-Cardiovascular Programme exhibit before and after the intervention?

Participants will undergo two semi-structured interviews: one prior to, and one following, their involvement in the MASH-Cardiovascular Programme at Hospital de Sant Pau i la Santa Creu, Barcelona.

03

Conditions studied

  • Metabolic Dysfunction Associated Steatohepatitis (MASH)

Browse trials for

Keywords

  • Qualitative
  • MASH
  • MASLD
  • Perceptions
  • Semi-structured interviews
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will consist of individuals diagnosed with MASH who are referred to the multidisciplinary MASH-Cardiovascular Programme at Hospital de la Santa Creu i Sant Pau in Barcelona.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who voluntarily agree to participate in the MASH-Cardiovascular Programme.
  • Patients followed in the outpatient hepatology/gastroenterology clinic at Hospital de Sant Pau with a diagnosis of MASH and fibrosis stage F2-F4.
  • Patients aged between 18 and 75 years.
  • Patients with a ≥ 27 kg/m².
  • Patients who consent to participate in the study-specific interviews.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not agree to participate in the study-specific interviews.
  • Patients meeting exclusion criteria of the MASH-Cardiovascular Programme:
  • Patients with decompensated liver cirrhosis.
  • Patients who are vegetarians or have dietary habits/preferences that prevent adherence to standard-of-care nutritional guidelines.
  • Patients with moderate-to-severe alcohol consumption (>20 g/day for women and >40 g/day for men).
  • Patients with an \< 30 mL/min.
  • Patients with malnutrition.
  • Patients with type 1 diabetes or other forms of diabetes.
  • Patients who are candidates for bariatric surgery.
  • Patients with active .
  • Patients with advanced or unstable heart failure.
  • Patients with eating disorders or severe psychiatric illness.
  • Patients currently enrolled in another clinical trial.
  • Pregnant women or women planning to become pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Perceptions

    Perceptions explored through semi-structured interviews

    Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)

  2. Attitudes and expectatives

    Attitudes and expectatives explored through semi-structured interviews

    Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)

  3. MASH-related knowledge

    MASH-related knowledge explored through semi-structured interviews

    Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)

  4. Unmet needs

    Unmet needs explored through semi-structured interviews

    Time frame: At baseline (within two weeks before starting the programme) and at one-year follow-up (within two weeks before and after completing the programme)

07

Study locations

2 of 2 sites recruiting
  • IR Sant Pau
    Barcelona, 08041, Spain
    Recruiting
    • Marina Idalia Rojo López Barcelona · Contactmrojo@santpau.cat · +34 93 556 56 17
  • IR Sant Pau
    Barcelona, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 88 non-industry observational studies under Fatty Liver, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 68. This study's planned 30 months is below that.

Counting every sponsor, half of 97 studies reached it within 33 months; a quarter within 20 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Sep 23, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Dec 20, 2027
CompletionEst.
Jan 20, 2028
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07188220
Responsible party
Sponsor
First posted
Sep 23, 2025
Start date
Jun 3, 2025
Primary completion
Dec 20, 2027 (estimated)
Completion
Jan 20, 2028 (estimated)
Last update
Sep 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion